Nakashima Daiki, Mori Eri, Otori Nobuyoshi
Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan.
Respir Med Case Rep. 2024 Jan 3;47:101968. doi: 10.1016/j.rmcr.2023.101968. eCollection 2024.
Dupilumab inhibits interleukin-4Rα and suppresses type 2 inflammation. Careful administration of dupilumab is required because it increases the blood eosinophil count secondary to a decrease in local eosinophil counts, sometimes resulting in eosinophilic complications. We herein report a case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab. A 54-year-old man with a history of eosinophilic pneumonia presented to our hospital with symptoms of cough, fever, and phlegm production six months after beginning dupilumab administration for recurrent chronic rhinosinusitis. When using dupilumab, it is essential to carefully monitor patients' eosinophil trends and pulmonary symptoms.
度普利尤单抗可抑制白细胞介素-4Rα并抑制2型炎症。由于度普利尤单抗会使局部嗜酸性粒细胞计数减少，继而导致血液嗜酸性粒细胞计数增加，有时会引发嗜酸性粒细胞相关并发症，因此需要谨慎使用。我们在此报告1例从贝那利珠单抗转换为度普利尤单抗治疗后复发的慢性嗜酸性粒细胞性肺炎病例。一名有嗜酸性粒细胞性肺炎病史的54岁男性，在开始使用度普利尤单抗治疗复发性慢性鼻-鼻窦炎6个月后，因咳嗽、发热和咳痰症状前来我院就诊。使用度普利尤单抗时，必须仔细监测患者的嗜酸性粒细胞变化趋势和肺部症状。
Zotero 插件
